UroGen Pharma FY2023: JELMYTO revenue $82.7M (+28% YoY), net loss narrows, UGN-102 NDA on track

UroGen Pharma Ltd.

Full year JELMYTO net revenue $82.7M, up ~28% YoY from $64.4M; Q4 revenue $23.5M (+30% YoY).
Net loss narrowed to $102.2M ($3.55/share) for FY2023 from $109.8M ($4.81/share) in 2022.
Rolling NDA for UGN-102 initiated Jan 2024; completion target Sep 2024, potential FDA decision Q1 2025.
Licensed next-gen mitomycin formulations (UGN-103/104) from medac with IP protection until Dec 2041.
Restructured Pharmakon loan: lower interest rate, deferred payback, up to $100M additional credit facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

UroGen Pharma Ltd. reported the fourth quarter of 2023 results: revenue $23.5 million.

Period: the fourth quarter of 2023
Revenue: $23.5 million
Result: reported results

Exact text from the filing

UroGen reported JELMYTO net product revenues of $23.5 million in the fourth quarter of 2023, compared to $18.1 million for the same period in 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

UroGen Pharma Ltd. reported the full year 2023 results: revenue $82.7 million.

Period: the full year 2023
Revenue: $82.7 million
Result: reported results

Exact text from the filing

Net JELMYTO product revenue for the full year 2023 was $82.7 million, compared to $64.4 million in 2022.

View on SEC.gov

1049 earnings releases filed in the last 30 days. Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-24-067432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.